• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections

tetano

Editor, Senior Moderator
Front Immunol


. 2022 Feb 24;13:773652.
doi: 10.3389/fimmu.2022.773652. eCollection 2022.
Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections


Yukiya Kurahashi[SUP] 1 [/SUP], Silvia Sutandhio[SUP] 1 [/SUP], Koichi Furukawa[SUP] 1 [/SUP], Lidya Handayani Tjan[SUP] 1 [/SUP], Sachiyo Iwata[SUP] 2 [/SUP], Shigeru Sano[SUP] 3 [/SUP], Yoshiki Tohma[SUP] 3 [/SUP], Hiroyuki Ohkita[SUP] 4 [/SUP], Sachiko Nakamura[SUP] 4 [/SUP], Mitsuhiro Nishimura[SUP] 1 [/SUP], Jun Arii[SUP] 1 [/SUP], Tatsunori Kiriu[SUP] 5 [/SUP], Masatsugu Yamamoto[SUP] 6 [/SUP], Tatsuya Nagano[SUP] 6 [/SUP], Yoshihiro Nishimura[SUP] 6 [/SUP], Yasuko Mori[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the virus responsible for the Coronavirus Disease 2019 (COVID-19) pandemic. The emergence of variants of concern (VOCs) has become one of the most pressing issues in public health. To control VOCs, it is important to know which COVID-19 convalescent sera have cross-neutralizing activity against VOCs and how long the sera maintain this protective activity.
Methods: Sera of patients infected with SARS-CoV-2 from March 2020 to January 2021 and admitted to Hyogo Prefectural Kakogawa Medical Center were selected. Blood was drawn from patients at 1-3, 3-6, and 6-8 months post onset. Then, a virus neutralization assay against SARS-CoV-2 variants (D614G mutation as conventional strain; B.1.1.7, P.1, and B.1.351 as VOCs) was performed using authentic viruses.
Results: We assessed 97 sera from 42 patients. Sera from 28 patients showed neutralizing activity that was sustained for 3-8 months post onset. The neutralizing antibody titer against D614G significantly decreased in sera of 6-8 months post onset compared to those of 1-3 months post onset. However, the neutralizing antibody titers against the three VOCs were not significantly different among 1-3, 3-6, and 6-8 months post onset.
Discussion: Our results indicate that neutralizing antibodies that recognize the common epitope for several variants may be maintained for a long time, while neutralizing antibodies having specific epitopes for a variant, produced in large quantities immediately after infection, may decrease quite rapidly.

Keywords: COVID-19; SARS-CoV-2; breadth; neutralization; variants.
 
Back
Top Bottom